Abstract
Erythropoietin (EPO) has been shown to be a key cytokine in the production of erythrocytes from erythroblasts. Recently, attempts have been made to adopt EPO as a drug target for neuroprotection in selected neurological pathologies. In the current study, a novel EPO-derived peptide which mimics the weak binding site of EPO to its receptor (MK-X) was generated. Experimental results demonstrated that MK-X was able to ameliorate neuronal death due to reactive oxygen species and conditions of oxidative stress similar to EPO. In addition, MK-X induced long-lasting Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and Akt activation. Furthermore, treatment with inhibitors of ERK1/2 and Akt abolished the neuroprotective effect of MK-X. Unlike EPO, however, MK-X did not induce cellular proliferation. Collectively, the results of the current study suggested that MK-X may be useful as a novel neuroprotective reagent.
Keywords: Erythropoietin receptor, erythropoietin, neuronal death, peptide, proliferation, reactive oxygen species.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress
Volume: 15 Issue: 8
Author(s): Seung-Jun Yoo, Bongki Cho, Chanil Moon, Seong-Woon Yu and Cheil Moon
Affiliation:
Keywords: Erythropoietin receptor, erythropoietin, neuronal death, peptide, proliferation, reactive oxygen species.
Abstract: Erythropoietin (EPO) has been shown to be a key cytokine in the production of erythrocytes from erythroblasts. Recently, attempts have been made to adopt EPO as a drug target for neuroprotection in selected neurological pathologies. In the current study, a novel EPO-derived peptide which mimics the weak binding site of EPO to its receptor (MK-X) was generated. Experimental results demonstrated that MK-X was able to ameliorate neuronal death due to reactive oxygen species and conditions of oxidative stress similar to EPO. In addition, MK-X induced long-lasting Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and Akt activation. Furthermore, treatment with inhibitors of ERK1/2 and Akt abolished the neuroprotective effect of MK-X. Unlike EPO, however, MK-X did not induce cellular proliferation. Collectively, the results of the current study suggested that MK-X may be useful as a novel neuroprotective reagent.
Export Options
About this article
Cite this article as:
Yoo Seung-Jun, Cho Bongki, Moon Chanil, Yu Seong-Woon and Moon Cheil, Neuroprotective Effects of an Erythropoietin-Derived Peptide in PC1 2 Cells under Oxidative Stress, CNS & Neurological Disorders - Drug Targets 2016; 15 (8) . https://dx.doi.org/10.2174/1871527315666160813223329
DOI https://dx.doi.org/10.2174/1871527315666160813223329 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on DNA & Gene Sequences Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
CNS & Neurological Disorders - Drug Targets MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Opioid-induced Cardioprotection
Current Pharmaceutical Design The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research Snake Venom Derived Molecules in Tumor Angiogenesis and its Application in Cancer Therapy; An Overview
Current Topics in Medicinal Chemistry Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Effects of Maternal Obesity on Maternal and Fetal Health
Current Women`s Health Reviews Modulation of Fatty Acids Oxidation in Heart Failure by Selective Pharmacological Inhibition of 3-Ketoacyl Coenzyme-A Thiolase
Current Clinical Pharmacology Therapeutic Approaches in Vascular Repair Induced by Adult Bone Marrow Cells and Circulating Progenitor Endothelial Cells
Current Pharmaceutical Design Effects of Nicotine During Pregnancy: Human and Experimental Evidence
Current Neuropharmacology The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Rosuvastatin may have Neuroprotective Effect on Spinal Cord Ischemia Reperfusion Injury
CNS & Neurological Disorders - Drug Targets RNAi in Clinical Studies
Current Medicinal Chemistry